Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

 61.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 71.50p
  • 52 Week Low: 49.00p
  • Currency: UK Pounds
  • Shares Issued: 70.57m
  • Volume: 17,805
  • Market Cap: £43.40m
  • RiskGrade: 22

Tissue Regenix to save £0.4m with move across Leeds

By Josh White

Date: Monday 17 Aug 2020

LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix announced the relocation of its UK head office and manufacturing facilities to Garforth, Leeds, from November on Monday.
The AIM-traded firm said the strategic decision to relocate its UK operations from nearby Swillington, Leeds, was made as part of its ongoing overhead cost saving initiatives.

It said it was expected to reduce its overhead spend by more than £0.4m on an annualised basis, from 2021.

As part of the relocation programme, the group would outsource elements of the production cycle relating to testing and packaging, but would retain its processing capabilities, including the manufacturing of 'OrthoPure XT'.

"We remain committed to reducing our overhead cost base to drive us towards a position of break-even," said interim chief executive officer Gareth Jones.

"Following a review of our near-term activity, this relocation will allow us to reduce our manufacturing footprint and associated costs, whilst importantly protecting the supply of our products.

"We also remain within the Leeds and York area to continue to support our local community and retain our valuable employee base."

At 1454 BST, shares in Tissue Regenix were up 10% at 0.34p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 61.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 71.50p
52 Week Low 49.00p
Volume 17,805
Shares Issued 70.57m
Market Cap £43.40m
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.53% below the market average41.53% below the market average41.53% below the market average41.53% below the market average41.53% below the market average
59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average
Price Trend
62.94% above the market average62.94% above the market average62.94% above the market average62.94% above the market average62.94% above the market average
36.21% above the sector average36.21% above the sector average36.21% above the sector average36.21% above the sector average36.21% above the sector average
Income Not Available
Growth
21.29% above the market average21.29% above the market average21.29% above the market average21.29% above the market average21.29% above the market average
19.27% above the sector average19.27% above the sector average19.27% above the sector average19.27% above the sector average19.27% above the sector average

TRX Dividends

No dividends found

Trades for 17-May-2024

Time Volume / Share Price
13:58 4,844 @ 61.80p
13:52 4,830 @ 62.00p
12:37 83 @ 61.10p
10:58 2 @ 61.10p
10:05 203 @ 61.80p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page